PATENT CLAIM ANALYSIS

Application Number: 16066921
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-01
Patent Classification: ["514", "365000"]

Abstract:
The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.

Claim (Index 175):
The method of  claim 174 , wherein said reduction is by from about 40% to about 50% relative to a measurement of the amplitude of uterine contractions in said subject recorded prior to said providing.

Metadata:
- Claim Count in Document: 115.0
- Percentile: 98.0
- Lexical Diversity: 1.41667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14987586', '15231549', '15729046', '10069744', '13486502']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8084236450107352
- 35 USC 102 Novelty (BERT): 0.540500988574602
- Combined Prediction Score: 0.7816313793671219
- Mean Citation Score: 351.3474
- Max Citation Score: 392.481
- Similarity Product: 253.54533355432747

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test